- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07342582
L'étude RHINO (Rhinovirus Hospitalization and Investigation of Nasal-airway Omics)
Identification du fardeau de l'hospitalisation dû au rhinovirus (RV) chez les enfants et mécanismes de pathogénèse par profilage moléculaire des voies respiratoires
The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Aim 1: Involves the prospective creation of a cohort of generally healthy children 12 to 36 months to be followed longitudinally for 36 months in an observational study. To determine the frequency of virus infection with RV and other respiratory viruses, children will have two swabs of the nasal mucosa performed whenever they develop an acute respiratory illness (upper respiratory symptoms lasting more than 24 hours) and four times a year for surveillance. One swab will be of the anterior nose and will be used for identification of viruses, and a second mid-turbinate swab will be used for host transcriptomics. This will allow the investigators to create many samples from both symptomatic and asymptomatic infections. The samples will be used to develop a host signature to discriminate symptomatic and asymptomatic infection.
Aim 2a: Involves the evaluation of generally healthy children hospitalized at AFCH with acute, lower respiratory tract infections including bronchiolitis, asthma, acute hypoxemic respiratory failure and community acquired pneumonia. There will also be the evaluation of infants less than 6 months of age who may become ill with an RV syndrome. These children will be evaluated with two nasal swabs as above. This allows the identification of children infected with RV and other respiratory viruses. Application of the host signature developed in Aim 1 will determine the actual proportion of those children who are infected with RV whose illness (clinical symptoms) is caused by RV.
Aim 2b: Involves the prospective creation of a cohort of generally healthy children 5 to 17.5 years old to be sampled on an as-needed basis to serve as age- and season-matched controls for the Hospitalized Group. To determine the frequency of virus infection with RV and other respiratory viruses, 2 healthy children will provide a single swab of the nasal mucosa within 2 weeks of each hospitalized participant who is 5-17.5 years of age. The one swab will be of the anterior nose and will be used for identification of viruses. Age matching will occur within 3 groups:
- Ages 5-8 years old: n=50
- Ages 9-13 years old: n=30
- Ages 14-17.5 years old: n=20
Aim 3: Use parallel bulk and single cell RNA sequencing (scRNA-seq) to identify targetable processes of acute, severe LRT caused by RV. The investigators hypothesize that integrated bulk RNA-sequencing and scRNA-seq will identify immune/inflammatory defects and targets for intervention. Bulk and scRNA-seq on respiratory samples from well-characterized patients with severe RV disease will be performed to test this hypothesis and to compare samples obtained from those with non-severe disease.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Research Nurses
- Numéro de téléphone: 608-228-4940
- E-mail: reserachnurses@pediatrics.wisc.edu
Lieux d'étude
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- Recrutement
- University of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Aim 1: Generally healthy male and female children 12 to 36 months of age living in Dane County and surrounding areas representative of the general demographics of the county.
Aim 2a: Hospitalized male and female children between newborn and 17.5 years of age with acute onset lower respiratory tract infections. These children will span all demographic and socioeconomic groups.
Aim 2b: Generally healthy male and female children 5 to 17.5 years of age living in Dane County and surrounding areas representative of the general demographics of the county.
La description
Inclusion Criteria (Aim 1 and Aim 2b Community Groups):
- Parent/legal guardian is willing and able to provide informed consent in English.
- Willing to comply with all study procedures and be available for the duration of the study.
- Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
- Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
- Current patient within primary care system at UW Health
Inclusion Criteria (Aim 2a: Hospitalized Group):
- Parent/legal guardian is willing and able to provide informed consent in English.
- Admitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
- Children under 17.5 years of age at the time of enrollment
- Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission
Exclusion Criteria (all participants):
- Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
- Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
- Presence of tracheostomy or gastrostomy tube
- Previously enrolled a different group in the study
- Other child in the same household already enrolled in the study
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Exclusion Criteria (Aim 1: Community Group Only):
- History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
- Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment
Exclusion Criteria (Aim 2: Hospitalized Group Only):
- History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
- A positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
- Non-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
- Uncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).
Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):
- Born prematurely, less than 32 weeks 0 days gestational age
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Younger Community Cohort (12-36 months of age)
Quarterly Surveillance Nasal Swabs and Nasal Swabs targeted around respiratory symptoms for up to 36 months of age, participants will provide one anterior and one mid-turbinate nasal swab sample |
Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance. Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection Caregivers are surveyed 7-13 days after sick sample collection |
|
Hospitalized Cohort of Infants and Children
Generally healthy infants and children hospitalized for respiratory illness will provide one anterior and one mid-turbinate nasal swab sample |
2 nasal swabs collected upon consent, one anterior and one mid-turbinate For hospitalized participants who opt to induce sputum, 3 medications will be used to obtain the sample, albuterol sulfate solution and hypertonic saline (3% solution) administered via nebulizer and and lidocaine spray (4% solution) via atomizer to the nose. For hospitalized participants with pneumonia who opt for research blood draw or induced sputum, optional administration of oral sucrose (Sweet-Ease) may occur at the discretion of the treating provider.
Autres noms:
|
|
Older Community Cohort (5 to 17.5 years of age)
Age-matched controls for older children in the Hospitalized Group, will be called upon as needed based on enrollment of hospitalized patients |
Participants will be enrolled as needed based on enrollment of hospitalized patients |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objectif 1 : Signature transcriptomique nasale unique des infections cliniques au rhinovirus
Délai: données collectées jusqu'à 36 mois
|
données collectées jusqu'à 36 mois
|
|
|
Aim 1: Summary of Rhinovirus Types Identified in Community Cohort
Délai: data collected up to 36 months
|
To test study hypotheses, the study team will identify the circulating RV types in symptomatic and asymptomatic children. |
data collected up to 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Aim 2: Summary of Rhinovirus Types Identified in lower respiratory tract (LRT) infections and upper respiratory tract infections (URI), Reported as Percent in Common
Délai: data collected up to 36 months
|
To test the hypothesis that there will be an 80 percent overlap between RV types causing acute LRT and URI, investigators will compare all RV types identified in age-matched hospitalized and ambulatory children. |
data collected up to 36 months
|
|
Aim 2: Proportion of Hospitalized Cohort with lower respiratory infections attributable to Rhinovirus
Délai: data collected up to 36 months
|
The investigators will use host nasal transcriptomics derived from symptomatic and asymptomatic children with RV infection to determine the proportion of age-matched hospitalized LRT infections actually attributable to RV. |
data collected up to 36 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Ellen R Wald, MD, UW School of Medicine and Public Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-1076
- SMPH\PEDIATRICS\INFECT DIS (Autre identifiant: UW Madison)
- 1R01AI182200-01A1 (Subvention/contrat des NIH des États-Unis)
- Protocol Version 8/25/26 (Autre identifiant: UW Madison)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
This study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-funded research that generates large-scale human or non-human genomic data, as well as the use of these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.
Délai de partage IPD
Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the study team at UW-Madison.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .